Polyplus Transfection Licenses Kempbio For Mammalian Transient Transfection Technology
5/18/2010 2:29:31 PM
Strasbourg, May 18, 2010 – Polyplus-transfection SA, a privately-held company developing innovative solutions for molecular and cellular biology, announced today that Kempbio, Inc., a company dedicated to providing high quality bioservices to the biotechnology and biopharmaceutical industry, has signed a license agreement to use polyethylenimine (PEI) for the transfection of cells used for the production of recombinant proteins.
By signing this license, Kempbio becomes one of Polyplus’ sub-licensees for the use of PEI technology for the expression of proteins on milligram and gram scales using the human cell line HEK-293 and other mammalian host cells. The production of recombinant proteins in human cell lines results in authentic human post-translational processing providing advantages for the stability and biological activity of proteins useful in the development of human therapeutics and diagnostic reagents.
“We are truly delighted to sign this license agreement with Kempbio, a company offering quality cell culture and protein expression services,” said Mark Bloomfield, CEO of Polyplus-transfection. “PEI is clearly the reagent of choice for research into large-scale mammalian transient transfection, and this agreement allows Kempbio to use PEI for its transfection services offering. Our business relationship with Kembio also demonstrates the significant value of our intellectual property rights in the field of PEI-mediated nucleic acid delivery.”
Financial terms were not disclosed.
About Polyplus-transfection SA
Polyplus-transfection SA is a biotechnology company researching, developing, manufacturing and marketing innovative solutions for scientists working in molecular and cell biology. Located in the Parc d’Innovation at Illkirch close to the city and University of Strasbourg in Eastern France, the company has been producing and selling its proprietary range of transfection reagents and technologies since 2001. The multidisciplinary Polyplus R&D team includes chemists, molecular and cellular biologists. Polyplus-transfection recently extended its product offering to molecular biologists with the launch and commercialization of ZNA (TM) modified oligonucleotides. The company holds a broad portfolio of patents and licenses in the fields of nucleic acid delivery and modified oligonucleotides. Polyplus is an ISO 9001 accredited company. For more information, please visit the Polyplus-transfection web site at:
About Kempbio, Inc.
Kempbio, Inc. is a new company with a solid foundation in the bioservices industry. Our scientists have been successfully developing processes and expressing proteins for biotechnology and biopharmaceutical research programs for over 15 years. Our expertise in mammalian cell culture and the baculovirus expression system ensure optimal results for your expression project. Kempbio, Inc. is focused on technologies that we have mastered and we offer high-quality services to meet your research needs. http://www.kempbioinc.com.
For additional information please contact Kempbio at:firstname.lastname@example.org
comments powered by